Pancreatic Cancer Research

ResearcherChiba UniversityActive in the last 2 years

Yohei Miyagi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0056-7010; OpenAlex author ID A5076512316. Sources: OpenAlex.

Their work

Papers
23 (first author 1, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
42
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: 3 papers · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 4 papers · 2026: 3 papers

Papers 23

  1. Tissue Factor as a Prognostic and Therapeutic Biomarker in Resected Pancreatic Cancer. Last author DOI 10.1245/s10434-026-19380-z↗
  2. ASO Author Reflections: Tissue Factor and Tumor Biology in Resected Pancreatic Cancer. Last author DOI 10.1245/s10434-026-19510-7↗
  3. Tumor-associated tissue-resident macrophages drive pancreatic cancer progression through IGF1-IGF1R signaling Co-author DOI 10.64898/2026.05.08.723679↗
  4. A pancreatic cancer organoid incorporating macrophages reveals the correlation between the diversity of tumor-associated macrophages and cancer cell survival. Co-author DOI 10.1016/j.biomaterials.2024.122838↗
  5. Protocol for generating a pancreatic cancer organoid associated with heterogeneous tumor microenvironment. Co-author DOI 10.1016/j.xpro.2024.103539↗
  6. Integrated cell atlas and tumoroids chart pancreatic cancer therapeutic targets Co-author DOI 10.1101/2025.09.30.679518↗
  7. Overexpression of Nuclear Factor of Activated T-cells (NFAT) Transcription Factors Drives Chemoresistance and Poor Outcomes in Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18186-9↗
  8. Evaluation of pancreatic cancer specimens for comprehensive genomic profiling. Last author DOI 10.1111/pin.13416↗
  9. Incorporation of human iPSC-derived stromal cells creates a pancreatic cancer organoid with heterogeneous cancer-associated fibroblasts. Co-author DOI 10.1016/j.celrep.2023.113420↗
  10. Reconstructing cell interactions and state trajectories in pancreatic cancer stromal tumoroids Co-author DOI 10.1101/2022.02.14.480334↗
  11. Authors' reply to the Letter to the Editor: Tissue factor and its procoagulant activity on cancer-associated thromboembolism in pancreatic cancer. Last author DOI 10.1111/cas.15324↗
  12. Tissue factor and its procoagulant activity on cancer-associated thromboembolism in pancreatic cancer. Last author DOI 10.1111/cas.15106↗
  13. Possible Role of Cytochrome P450 1B1 in the Mechanism of Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.3390/biomedicines9101396↗
  14. Novel targets identified by integrated cancer-stromal interactome analysis of pancreatic adenocarcinoma. Last author DOI 10.1016/j.canlet.2019.10.031↗
  15. The impact of SPARC expression on the survival of pancreatic ductal adenocarcinoma patients after curative resection. Co-author DOI 10.7150/jca.28660↗
  16. Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-Transferase Pi expression for the efficacy and safety of FOLFIRINOX in patients with unresectable pa… Co-author PMID 30416859↗
  17. Clinical implications of ribonucleotide reductase subunit M1 in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherap… First author DOI 10.3892/ol.2017.5935↗
  18. Predictive role of human equilibrative nucleoside transporter 1 in patients with pancreatic cancer treated by curative resection and gemcitabine-only adjuvant … Co-author DOI 10.3892/ol.2017.6220↗
  19. Clinical implications of dihydropyrimidine dehydrogenase expression in patients with pancreatic cancer who undergo curative resection with S-1 adjuvant chemoth… Co-author DOI 10.3892/ol.2017.6295↗
  20. Locked Nucleic Acid In Situ Hybridization Analysis of MicroRNA-21 Predicts Clinical Outcome in Patients After Resection for Pancreatic Cancer Treated with Adju… Last author PMID 26977002↗
  21. The clinical significance of SWI/SNF complex in pancreatic cancer. Last author DOI 10.3892/ijo.2012.1723↗
  22. The cellular level of histone H3 lysine 4 dimethylation correlates with response to adjuvant gemcitabine in Japanese pancreatic cancer patients treated with su… Last author DOI 10.1016/j.ejso.2012.08.008↗
  23. Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adju… Last author DOI 10.1245/s10434-011-2054-z↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Soichiro Morinaga · 16 shared papers, 2012–2026 · strength 1.85
  2. Satoshi Kobayashi · 8 shared papers, 2016–2026 · strength 1.16
  3. Makoto Ueno · 10 shared papers, 2016–2026 · strength 1.13
  4. Shiro Koizume · 4 shared papers, 2021–2026 · strength 1.08
  5. Shunsuke Tabe · 4 shared papers, 2023–2026 · strength 0.86
  6. Hideki Taniguchi · 4 shared papers, 2023–2026 · strength 0.86
  7. Kenta Takeuchi · 4 shared papers, 2023–2026 · strength 0.86
  8. Masayuki Ohtsuka · 4 shared papers, 2023–2026 · strength 0.86
  9. Masaaki Murakawa · 7 shared papers, 2016–2026 · strength 0.75
  10. Mariko Kamiya · 2 shared papers, 2026 · strength 0.74
  11. Yuya Yamamoto · 3 shared papers, 2025–2026 · strength 0.70
  12. Naoto Yamamoto · 7 shared papers, 2012–2025 · strength 0.69
  13. Kota Washimi · 3 shared papers, 2024–2026 · strength 0.63
  14. Toru Aoyama · 6 shared papers, 2016–2025 · strength 0.51
  15. Manabu Morimoto · 7 shared papers, 2016–2021 · strength 0.50
  16. Yukihiko Hiroshima · 3 shared papers, 2020–2025 · strength 0.49
  17. Ryotaro Eto · 2 shared papers, 2025–2026 · strength 0.47
  18. Takanori Konishi · 2 shared papers, 2025–2026 · strength 0.47
  19. Yuto Kamioka · 2 shared papers, 2025–2026 · strength 0.44
  20. Shinnosuke Kawahara · 2 shared papers, 2025–2026 · strength 0.44
  21. J. Gray Camp · 2 shared papers, 2022–2025 · strength 0.32
  22. Ryo Okuda · 2 shared papers, 2022–2025 · strength 0.32
  23. Robert M. Hoffman · 2 shared papers, 2020–2025 · strength 0.29
  24. Takashi Oshima · 4 shared papers, 2017–2020 · strength 0.27
  25. Quan Xu · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.